卡培他滨联合马来酸吡咯替尼与甲苯磺酸拉帕替尼治疗HER-2阳性晚期乳腺癌患者的近期效果及安全性研究  

Efficacy and safety of Capecitabine combined with Pyrrotinib in treatment of advanced breast cancer patients with HER-2 positive

作　　者：梁晓丹 许欢欢 张强[1] 柴丽君[1] Liang Xiaodan;Xu Huanhuan;Zhang Qiang;Chai Lijun(Department of breast surgery,The Second Affiliated Hospital of Zhengzhou University,Zhengzhou 450014,China)

机构地区：[1]郑州大学第二附属医院乳腺外科,郑州450014

出　　处：《河南外科学杂志》2024年第5期18-21,共4页Henan Journal of Surgery

摘　　要：目的比较卡培他滨联合马来酸吡咯替尼与甲苯磺酸拉帕替尼治疗HER-2阳性晚期乳腺癌患者的近期效果及安全性。方法选取2021-06—2022-10就诊于郑州大学第二附属医院乳腺外科的60例HER-2阳性晚期乳腺癌患者,依据随机表法分为2组,各30例。观察组采用卡培他滨联合马来酸吡咯替尼方案,对照组采用卡培他滨联合甲苯磺酸拉帕替尼方案。以21 d为1个治疗周期,治疗至疾病进展或不能耐受药物副反应为终点。比较2组患者的临床疗效、疾病控制率(DCR)、疾病的无进展时间(PFS)及不良反应发生率。结果治疗2个周期后,观察组患者的DCR高于对照组,治疗后6个月、12个月及中位PFS均长于对照组,差异均有统计学意义(P<0.05)。2组患者副反应发生率的差异无统计学意义(P>0.05)。结论与马来酸吡咯替尼联合甲苯磺酸拉帕替尼比较,卡培他滨联合马来酸吡咯替尼治疗晚期HER-2阳性型乳腺癌,能提高患者的DCR、延长PFS,且不增加副反应发生率。Objective To study the efficacy and safety of Capecitabine combined with Pyrrotinib in the treatment of advanced breast cancer patients with HER-2 positive.Methods A total of 60 patients with HER-2 positive advanced breast cancer were selected from the related department of our hospital from June 2021 to October 2022 for the study.According to the principle of random allocation,the 60 patients were divided into the experimental group and the control group randomly,30 cases in each group.The experimental group was treated with capecitabine tablets combined with pyrrotinib maleate tablets,and the control group was given capecitabine tablets combined with lapatinib toluene sulfonate.Treatment was performed every 21 days until the disease progressed or the related toxic reactions could not be tolerated.The clinical efficacy,DCR,PFS and the occurrence of adverse reactions were compared between the two groups.Results After 2 cycles of treatment,the DCR of the experimental group was higher than that of the control group,with statistically significant differences(P<0.05).The 6-month PFS,12-month PFS and median PFS in the experimental group were longer than those in the control group(P<0.05).There was no significant difference in the incidence of treatment-related adverse events between the two groups(P>0.05).Conclusion Pyrrotinib combined with capecitabine in the treatment of advanced breast cancer with positive HER-2 can improve DCR and prolong PFS in patients,and the application is safe and reliable,which is worthy of clinical promotion.

关 键 词：晚期乳腺癌 HER-2 马来酸吡咯替尼 甲苯磺酸拉帕替尼 

分 类 号：R737.9[医药卫生—肿瘤]